- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 30, 2023
Data Byte
With $125M goal, Structure’s IPO would be among NASDAQ’s largest in a year
Cross-border company aiming for offering that would rank fifth among biotechs listing on NASDAQ in past 12 months
BioCentury | Aug 5, 2022
Discovery & Translation
Daley lab’s iPSC-derived T cell differentiation method; plus Harbour’s CTLA-4 antibody and more
BioCentury’s roundup of translational news
BioCentury | Apr 1, 2022
Distillery Therapeutics
iPSC-derived cell therapy for diabetic microvascular complications
BioCentury | Jan 15, 2022
Management Tracks
Founder El-Hibri to retire from Emergent
Plus CEO Sandanayaka shifts to CSO at Nirogy, and updates from Angelini, Apie,
BioCentury | Jun 18, 2019
Distillery Therapeutics
APLN17 analog identified for abdominal aortic aneurysm
BioCentury | Aug 10, 2018
Targets & Mechanisms
Getting to function
How a new sarcopenia target could directly address muscle function deficits
Items per page:
1 - 10 of 13